New Combination Drug for Depression.
The American journal of nursing April 1, 2023 DOI: 10.1097/01.naj.0000925488.72453.63 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Population | Adults with major depressive disorder |
| Intervention | Dextromethorphan-bupropion |
| Topics | Depression |
| Key points | Auvelity is approved for treating major depressive disorder in adults but carries risks of suicidal thoughts in younger patients and seizures at higher doses. |
Abstract
Auvelity, an extended-release fixed combination of dextromethorphan and bupropion, is approved for the treatment of major depressive disorder in adults.Like all antidepressants, dextromethorphan-bupropion carries a boxed warning that it may increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Seizures can also occur and are more likely at higher doses.The most common adverse effects of dextromethorphan-bupropion include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, hyperhidrosis, anxiety, constipation, decreased appetite, and insomnia.